De Novo DQ Donor-Specific Antibodies Are Associated with Chronic Lung Allograft Dysfunction after Lung Transplantation

Summary

Of 340 recipients transplanted between 2008 and 2011, who had regular HLA-antibody testing for 24 months after transplant, the cumulative incidence of de novo donor-specific antibodies (dnDSA) was 47 percent at a median of 86 days, and 76 percent of those with dnDSA had DQ-DSA. According to the abstract, male sex and the use of ex vivo lung perfusion were associated with a higher risk of dnDSA, while greater HLA-DQB1 matching was protective. DQ-dnDSA preceded or coincided with the diagnosis of CLAD in all cases, and developing dnDSA was associated with about a twofold higher risk of CLAD (hazard ratio 2.04, 95 percent confidence interval 1.13 to 3.69). The study is observational. The abstract does not name the centre; the authorship includes Tereza Martinu.

Details

doi

10.1164/rccm.201509-1857oc

pmid

26967790

authors

Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, Chow CW, Martinu T, Azad S, Keshavjee S, Tinckam K

journal

American Journal of Respiratory and Critical Care Medicine

year

2016

volume

194

issue

5

pages

596-606

Sources and links

• Publisher record via DOI (primary)
• PubMed 26967790

Related

Links from this record

• supports: Humoral (antibody-mediated) alloimmunity
• related to: Autoantibodies
• coauthor: Tereza Martinu

Linked from (derived)

• supports: HLA donor-specific antibody and non-HLA antibody testing
• supports: Antibody-mediated rejection and donor-specific antibodies

Known gaps in this record

• full text not read (abstract only)
• funding statement and grant numbers
• author affiliations
• centre or centres not stated in the abstract